Fig. 1 · Structure

Documents & Downloads

Dacarbazine

Cat. No. A10281 CAS 4342-03-4
Dacarbazine is an antineoplastic chemotherapy drug used in the treatment of various cancers.Dacarbazine is a member of the class of alkylating agents, which destroy cancer cells by adding an alkyl group (CnH2n+1) to its DNA.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Nucleoside antimetabolite/analog

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 > 100 μM Antiproliferative activity against human A375 cells after 48 hrs by SRB assay [PMID: 20056548]
A-375 IC50 > 100 μM Antiproliferative activity against human A375 cells after 48 hrs by SRB assay [PMID: 18477505]
A-375 IC50 > 500 μM Cytotoxicity against human A375 cells after 48 hrs by MTT assay [PMID: 22560315]
A549 IC50 35 μg/mL Cytotoxicity against Homo sapiens (human) A549 cells assessed as cell viability by MTT assay 10.1007/s00044-007-9031-x
B16-F1 IC50 > 100 μM Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay [PMID: 20056548]
B16-F1 IC50 > 100 μM Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay [PMID: 18477505]
Fibroblast IC50 > 100 μM Cytotoxicity against human fibroblasts after 48 hrs by SRB assay [PMID: 20056548]
HeLa GI50 > 50 μM Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay [PMID: 24986661]
OVCAR-3 IC50 17.67 μM Cytotoxicity against human OVCAR3 cells after 6 days by MTT assay [PMID: 21131205]
SK-MEL-2 IC50 120 μM Cytotoxicity against human SK-MEL-2 cells after 6 days by MTT assay [PMID: 21131205]
UACC-62 IC50 11.83 μM Cytotoxicity against human UACC62 cells after 6 days by MTT assay [PMID: 21131205]
WM164 IC50 > 100 μM Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay [PMID: 20056548]
WM164 IC50 > 100 μM Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay [PMID: 17561392]

13 records · Scroll to view more

Dacarbazine Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Dacarbazine from 2 published references. In vitro models include primary hepatocytes isolated from male Sprague-Dawley rats.

Dacarbazine In Vitro Studies

In isolated rat hepatocytes, dacarbazine had a reported 2-h viability EC50 of 56 μM. At 56 μM, it increased cell injury and DCF fluorescence; catalase partially reduced both responses. These findings describe hepatocyte toxicity, rather than anticancer potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Dacarbazine-induced injury in isolated rat hepatocytes

Cell-based study · Primary hepatocytes isolated from male Sprague-Dawley rats (280–300 g) [1]

Dacarbazine caused hepatocyte injury and increased DCF fluorescence. Catalase and other tested antioxidants/scavengers reduced these responses. This is a normal-liver-cell toxicity model, not a melanoma potency assay. The pyridine analogue was tested separately and is excluded from this product record.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hepatocyte viability at 2 hEC50 56 μM[1]
Trypan-blue-positive cells after 3 hCytotoxicity (%) Control: 20 ± 2; DTIC (56 μM): 76 ± 4; DTIC + catalase (200 U/mL): 46 ± 2[1]
DCF fluorescence after 30 minFluorescence intensity units Control: 79 ± 4; DTIC (56 μM): 230 ± 4; DTIC + catalase (200 U/mL): 116 ± 5[1]

Literature-Reported Treatment Conditions

Treatment concentration
56 μM DTIC in mechanistic assays; EC50 is a separate 2-h viability endpoint.
Exposure duration
3 h for cytotoxicity; 30 min for ROS; EC50 determined at 2 h.
Method
Isolated hepatocytes (10^6 cells/mL), Krebs-Henseleit buffer pH 7.4, 37°C. Modulators preincubated for 30 min.
Co-treatment
Selected rescue comparison: catalase 200 U/mL plus DTIC; compared with DTIC alone and untreated control.
Reported limits
DTIC-specific stock solvent is not identified among the water/methanol stock procedures. Dose-response curve and three tested concentrations for EC50 were not shown. Table footnote specifies three separate experiments; number of donor rats is not specified.
Methods and source locations

Compound reported in the paper: Dacarbazine; Compound label in the paper: DTIC

Compound-level cellular toxicity evidence; no inference about Adooq lot performance, clinical liver injury, or anticancer IC50.

Experimental: Chemicals; Isolation and incubation of hepatocytes; Cell viability; ROS assay; Statistical analysis; Results and Discussion, Table 1 and footnotes

Hepatocyte viability at 2 h: Trypan-blue exclusion; authors defined EC50 as concentration reducing viability to 50% after 2 h. Regression used three concentrations; underlying dose-response data/curves were not shown. — Experimental: Isolation and incubation of hepatocytes; Results and Discussion, opening paragraph

Trypan-blue-positive cells after 3 h: Table 1: mean (SD), three separate experiments. DTIC differs from control and catalase combination differs from DTIC (each p < 0.05). — Table 1, None / Dacarbazine / +Catalase rows, cytotoxicity column and footnotes

DCF fluorescence after 30 min: DCFH-DA/DCF fluorimetry; Table 1 mean (SD), three separate experiments. DTIC differs from control and catalase combination differs from DTIC (each p < 0.05). — Table 1, None / Dacarbazine / +Catalase rows, ROS column and footnotes

Dacarbazine In Vivo Studies

In B16F1 melanoma-bearing C57BL/6 mice, dacarbazine was evaluated alone and with axitinib. The combination reduced tumor growth and tumor weight relative to vehicle but did not significantly improve these endpoints over axitinib alone. Dacarbazine monotherapy showed comparatively weaker tumor suppression. [2]

Dacarbazine and axitinib comparison in B16F1 melanoma-bearing mice

Animal study · Female C57BL/6 mice, 6–8 weeks old, 18–22 g, with subcutaneous B16F1 melanoma; randomized at average tumor volume 60–100 mm³. [2]

The four-arm experiment compared vehicle, DTIC, axitinib and their combination. Axitinib and the combination reduced tumor growth and tumor weight versus vehicle; adding DTIC did not significantly improve these endpoints over axitinib alone. DTIC showed comparatively weaker tumor suppression. No exact tumor size or percentage inhibition is extracted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth and excised tumor weightFour-arm comparison Axitinib and axitinib + DTIC versus vehicle: P < 0.001 as reported in Results; combination versus axitinib: no significant difference.[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dacarbazine monotherapy
80 mg/kg
Concurrent vehicle group: PBS i.p. daily for 5 days and 0.5% CMC twice daily for 2 weeks. DTIC formulation is stated as saline, so injected vehicle is not described identically.Comparatively weaker tumor suppression than axitinib-containing regimens; no exact value or significance against vehicle assigned.[2]
Axitinib comparator
25 mg/kg body weight
Concurrent vehicle group: PBS i.p. daily for 5 days and 0.5% CMC twice daily for 2 weeks. DTIC formulation is stated as saline, so injected vehicle is not described identically.Reduced tumor growth and tumor weight versus vehicle.[2]
Dacarbazine plus axitinib
DTIC 80 mg/kg plus axitinib 25 mg/kg body weight
Concurrent vehicle group: PBS i.p. daily for 5 days and 0.5% CMC twice daily for 2 weeks. DTIC formulation is stated as saline, so injected vehicle is not described identically.Reduced tumor growth and tumor weight versus vehicle, with no significant improvement over axitinib alone.[2]
Dacarbazine monotherapy
Model: Female C57BL/6 mice with subcutaneous B16F1 melanoma; 10 mice per group in growth experiment.
Route: Intraperitoneal
Frequency: Daily
Treatment course: 5 days
Vehicle: 0.9% NaCl
Reported limits: Exact tumor-harvest timing is inconsistent: methods say 14 days after last treatment; Figure 1 caption says day 14, and plot uses days after inoculation. No exact endpoint day assigned.
Axitinib comparator
Model: Female C57BL/6 mice with subcutaneous B16F1 melanoma; 10 mice per group in growth experiment.
Route: Oral gavage
Frequency: Twice daily
Treatment course: 14 days
Vehicle: 0.5% CMC
Reported limits: Exact tumor-harvest timing is inconsistent: methods say 14 days after last treatment; Figure 1 caption says day 14, and plot uses days after inoculation. No exact endpoint day assigned.
Dacarbazine plus axitinib
Model: Female C57BL/6 mice with subcutaneous B16F1 melanoma; 10 mice per group in growth experiment.
Route: DTIC intraperitoneal; axitinib oral gavage
Frequency: DTIC daily; axitinib twice daily
Treatment course: DTIC 5 days; axitinib 14 days
Vehicle: DTIC in 0.9% NaCl; axitinib in 0.5% CMC
Reported limits: Exact tumor-harvest timing is inconsistent: methods say 14 days after last treatment; Figure 1 caption says day 14, and plot uses days after inoculation. No exact endpoint day assigned.
Methods and source locations

Compound reported in the paper: Dacarbazine; Compound label in the paper: DTIC

Compound-level mouse-model evidence for single and combination treatment; does not validate this SKU lot or clinical efficacy.

Materials and methods: Animals; Treatment agents; Tumor therapy model; Statistical analysis. Results: first subsection; Figure 1A–C and caption

Tumor growth and excised tumor weight: Caliper tumor measurements and terminal excised tumor weights; Figure 1 caption: n = 10 mice/group, mean ± SEM, experiments performed three times. No pooled n inferred; no exact values estimated from plot. — Materials and methods: Animals; Treatment agents; Tumor therapy model; Statistical analysis. Results: first subsection; Figure 1A–C and caption

Dacarbazine monotherapy · Materials and methods: Animals; Treatment agents; Tumor therapy model; Statistical analysis. Results: first subsection; Figure 1A–C and caption

Axitinib comparator · Materials and methods: Animals; Treatment agents; Tumor therapy model; Statistical analysis. Results: first subsection; Figure 1A–C and caption

Dacarbazine plus axitinib · Materials and methods: Animals; Treatment agents; Tumor therapy model; Statistical analysis. Results: first subsection; Figure 1A–C and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 4342-03-4
Formula C6H10N6O
Molecular Weight 182.18
Synonyms DTIC
SMILES
CN(C)N/N=C/1\C(=NC=N1)C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 12 mg/mL (65.86 mM)
Water Warmed: 2 mg/mL (10.97 mM)
Ethanol Warmed: 1 mg/mL (5.48 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
0.5% CMC Na

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dacarbazine Research References

  1. [1] Marzieh Amirmostofian, Jalal Pourahmad Jaktaji, Zohreh Soleimani, et al. Synthesis and Molecular-cellular Mechanistic Study of Pyridine Derivative of Dacarbazine Iranian Journal of Pharmaceutical Research (2013). PMID: 24250631 Source material
  2. [2] Xiao-Hua Zhang, En-Qi Qiao, Zhenzhen Gao, et al. Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model Oncology Letters (2013). PMID: 23946779 DOI: 10.3892/ol.2013.1345 Source material

Added to your cart

View Cart Checkout
Loading...